Trial · NCT01969708
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 | Aflibercept | 18.9 | 95% Confidence Interval 16.62 to 21.15 | letters read | |
| Mean Change From Baseline in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Letter Score at Month 6 | Bevacizumab | 18.6 | 95% Confidence Interval 16.16 to 21.09 | letters read | |
| Number of Study Eyes With Gain of ≥15 Letters in Visual Acuity Letter Score at Month 6 | Aflibercept | 114 | study eyes | ||
| Number of Study Eyes With Gain of ≥15 Letters in Visual Acuity Letter Score at Month 6 | Bevacizumab | 106 | study eyes | ||
| Number of Study Eyes With Visual Acuity Letter Score of 70 or Better at Month 6 | Aflibercept | 101 | study eyes | ||
| Number of Study Eyes With Visual Acuity Letter Score of 70 or Better at Month 6 | Bevacizumab | 99 | study eyes | ||
| Mean Spectral-domain Optical Coherence Tomography Central Subfield Thickness | Aflibercept | 231.3 | 95% Confidence Interval 220.8 to 241.8 | um | |
| Mean Spectral-domain Optical Coherence Tomography Central Subfield Thickness | Bevacizumab | 287.9 | 95% Confidence Interval 269.4 to 306.4 | um | |
| Mean Change From Baseline in Spectral Domain Optical Coherence Tomography Central Subfield Thickness at Month 6 | Aflibercept | -425 | 95% Confidence Interval -461 to -389 | um | |
| Mean Change From Baseline in Spectral Domain Optical Coherence Tomography Central Subfield Thickness at Month 6 | Bevacizumab | -387 | 95% Confidence Interval -426 to -348 | um | |
| Number of Study Eyes With Central Subfield Thickness <300 μm, no Subretinal Fluid, no Intraretinal Fluid, and no Cystoid Spaces | Aflibercept | 92 | study eyes | ||
| Number of Study Eyes With Central Subfield Thickness <300 μm, no Subretinal Fluid, no Intraretinal Fluid, and no Cystoid Spaces | Bevacizumab | 49 | study eyes |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01969708/results